MA63136A1 - Agent thérapeutique contre le cancer résistant à un inhibiteur de parp - Google Patents

Agent thérapeutique contre le cancer résistant à un inhibiteur de parp

Info

Publication number
MA63136A1
MA63136A1 MA63136A MA63136A MA63136A1 MA 63136 A1 MA63136 A1 MA 63136A1 MA 63136 A MA63136 A MA 63136A MA 63136 A MA63136 A MA 63136A MA 63136 A1 MA63136 A1 MA 63136A1
Authority
MA
Morocco
Prior art keywords
parp inhibitor
therapeutic agent
cancer resistant
patient
resistance
Prior art date
Application number
MA63136A
Other languages
English (en)
Inventor
Hyun Ju Cha
Chang Seok Lee
Sang Woo Han
John Kim
Original Assignee
Onconic Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc. filed Critical Onconic Therapeutics Inc.
Priority claimed from KR1020220060706A external-priority patent/KR20220156468A/ko
Publication of MA63136A1 publication Critical patent/MA63136A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement ou la prévention du cancer solide d'un patient ayant une résistance à un inhibiteur de PARP. La composition pharmaceutique selon la présente invention peut réduire efficacement une taille de tumeur d'un patient ayant une résistance à un inhibiteur de PARP.
MA63136A 2021-05-18 2022-05-18 Agent thérapeutique contre le cancer résistant à un inhibiteur de parp MA63136A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210064278 2021-05-18
KR1020220060706A KR20220156468A (ko) 2021-05-18 2022-05-18 Parp 저해제 저항성 암 치료제
PCT/KR2022/007115 WO2022245131A1 (fr) 2021-05-18 2022-05-18 Agent thérapeutique contre le cancer résistant à un inhibiteur de parp

Publications (1)

Publication Number Publication Date
MA63136A1 true MA63136A1 (fr) 2024-06-28

Family

ID=84140612

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63136A MA63136A1 (fr) 2021-05-18 2022-05-18 Agent thérapeutique contre le cancer résistant à un inhibiteur de parp

Country Status (11)

Country Link
US (1) US20240238283A1 (fr)
JP (2) JP2024518509A (fr)
AU (1) AU2022276986B2 (fr)
BR (1) BR112023023815A2 (fr)
CA (1) CA3219248A1 (fr)
IL (1) IL308325A (fr)
MA (1) MA63136A1 (fr)
MX (1) MX2023013534A (fr)
UA (1) UA130396C2 (fr)
WO (1) WO2022245131A1 (fr)
ZA (1) ZA202310833B (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3012256A1 (fr) * 2013-06-17 2016-04-27 Shanghai Huilun Life Science & Technology Co., Ltd Composé hétérocyclique de benzimidazole-2-pipérazine, composition pharmaceutique le contenant, procédé de préparation et d'utilisation associé
EP3312177A2 (fr) * 2015-06-09 2018-04-25 Jeil Pharmaceutical Co., Ltd. Composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique le contenant
EP3321377A1 (fr) * 2015-07-06 2018-05-16 The Asan Foundation Procédé pour déterminer la sensibilité à un inhibiteur simultané contre la parp et la tankyrase
EP3721906A1 (fr) * 2017-12-06 2020-10-14 Jiangsu Hengrui Medicine Co., Ltd. Utilisation d'un inhibiteur de parp dans le traitement du cancer de l'ovaire résistant à la chimiothérapie ou du cancer du sein
WO2021013735A1 (fr) * 2019-07-19 2021-01-28 Astrazeneca Ab Inhibiteurs de parp1
WO2021048235A1 (fr) * 2019-09-10 2021-03-18 The Francis Crick Institute Limited Traitement du cancer à déficit de hr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US9907357B2 (en) 2015-09-24 2018-03-06 Nike, Inc. Fluid-filled chamber for an article of footwear
MX2020003770A (es) * 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
US20210106574A1 (en) * 2017-12-27 2021-04-15 Tesaro, Inc. Methods of Treating Cancer
EP4552696A3 (fr) * 2018-05-15 2025-11-05 Allarity Therapeutics Europe ApS Procédés de prédiction de la réactivité à un médicament chez des patients atteints d'un cancer
TWI725542B (zh) 2018-09-25 2021-04-21 日商東洋紡股份有限公司 水分散性之微粒子、抗微生物劑及生物膜去除劑

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3012256A1 (fr) * 2013-06-17 2016-04-27 Shanghai Huilun Life Science & Technology Co., Ltd Composé hétérocyclique de benzimidazole-2-pipérazine, composition pharmaceutique le contenant, procédé de préparation et d'utilisation associé
EP3312177A2 (fr) * 2015-06-09 2018-04-25 Jeil Pharmaceutical Co., Ltd. Composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique le contenant
EP3321377A1 (fr) * 2015-07-06 2018-05-16 The Asan Foundation Procédé pour déterminer la sensibilité à un inhibiteur simultané contre la parp et la tankyrase
EP3721906A1 (fr) * 2017-12-06 2020-10-14 Jiangsu Hengrui Medicine Co., Ltd. Utilisation d'un inhibiteur de parp dans le traitement du cancer de l'ovaire résistant à la chimiothérapie ou du cancer du sein
WO2021013735A1 (fr) * 2019-07-19 2021-01-28 Astrazeneca Ab Inhibiteurs de parp1
WO2021048235A1 (fr) * 2019-09-10 2021-03-18 The Francis Crick Institute Limited Traitement du cancer à déficit de hr

Also Published As

Publication number Publication date
UA130396C2 (uk) 2026-02-04
MX2023013534A (es) 2025-12-01
US20240238283A1 (en) 2024-07-18
AU2022276986B2 (en) 2025-07-03
BR112023023815A2 (pt) 2024-02-06
JP2024518509A (ja) 2024-05-01
WO2022245131A1 (fr) 2022-11-24
AU2022276986A1 (en) 2023-11-30
IL308325A (en) 2024-01-01
ZA202310833B (en) 2025-03-26
CA3219248A1 (fr) 2022-11-24
JP2026026362A (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
JOP20230190A1 (ar) مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
SV2009003283A (es) Inhibidores de la actividad de la akt
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
EP4119156A4 (fr) Médicament pour le traitement et/ou la prévention du cancer
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2021007484A (es) Compuestos nuevos y su uso en terapia.
PH12018500678A1 (en) Human plasma kallikrein inhibitors
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2021013318A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
EP4360649A4 (fr) Médicament pour le traitement et/ou la prévention du cancer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MA63136A1 (fr) Agent thérapeutique contre le cancer résistant à un inhibiteur de parp
EP4119157A4 (fr) Médicament pour le traitement et/ou la prévention du cancer
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
JOP20200246A1 (ar) مركب دوائي لعلاج مرض البهاق